Glucosuria >1000 mg/dL on Jardiance and Metformin is Expected and Therapeutic
High urinary glucose levels (>1000 mg/dL) in a patient taking empagliflozin (Jardiance) and metformin represent the intended pharmacologic effect of SGLT2 inhibitor therapy, not a treatment failure or cause for alarm. This is the mechanism by which empagliflozin provides its cardiovascular and renal benefits 1.
Mechanism of Action
Empagliflozin works by inhibiting SGLT2 in the proximal renal tubule, which normally reabsorbs approximately 90% of filtered glucose back into the bloodstream 1. By blocking this reabsorption, empagliflozin:
- Increases urinary glucose excretion by 60-100 grams per day 2
- Lowers the renal threshold for glucose, causing glucosuria even at normal blood glucose levels 1
- Results in urinary glucose levels of 3000-4000 mg/dL in clinical practice 3, 4
In clinical trials, empagliflozin 10 mg produced approximately 64 grams of urinary glucose daily, while 25 mg produced approximately 78 grams daily 1. This translates to 200-400 kcal/day energy loss through urine 5.
Clinical Implications
This is NOT a Problem
The high urinary glucose is:
- Therapeutic and intentional - it's how the drug works
- Associated with cardiovascular and renal protection independent of glucose-lowering effects 6, 7
- Maintained throughout treatment - the effect persists as long as the medication is taken 4
Important Monitoring Considerations
Do NOT use urine glucose testing to monitor glycemic control in patients on SGLT2 inhibitors 1. The FDA label explicitly states that SGLT2 inhibitors will cause positive urine glucose tests, and alternative methods (blood glucose monitoring, HbA1c) must be used instead 1.
Safety Monitoring Required
While glucosuria itself is expected, monitor for these SGLT2 inhibitor-related complications:
Volume Depletion Risk
- Osmotic diuresis from glucosuria increases urine volume by approximately 341 mL on day 1, stabilizing to 135 mL increase by day 5 1
- Higher risk in patients on diuretics, elderly, or those unable to maintain adequate fluid intake 8, 7
- Critical consideration: Patients who cannot autonomously replace fluid losses (stroke patients, cognitively impaired, bedridden) are at severe risk for hypernatremic dehydration 9
Genital Mycotic Infections
- Occur in approximately 6% of patients on SGLT2 inhibitors versus 1% on placebo 7
- Higher risk in women than men 2
- Usually mild and easily treated, but rare severe cases (Fournier's gangrene) reported 7
Euglycemic Ketoacidosis
- Can occur with minimal blood glucose elevation due to enhanced lipolysis and decreased ketone excretion 2
- Risk factors: insulin deficiency, acute illness, prolonged fasting, very low-carbohydrate diets 2, 7
- Use blood or urine ketone monitoring, not glucose levels, to detect ketoacidosis 7
Renal Function Monitoring
- Empagliflozin can be initiated with eGFR ≥20 mL/min/1.73 m² 7
- Initial eGFR decrease of ~5 mL/min occurs within 1-2 weeks, then stabilizes 2
- Continue therapy even if eGFR declines - cardiovascular and renal benefits persist at lower eGFR levels 6, 7
When to Reassess Therapy
Temporarily discontinue empagliflozin in these situations:
- Acute illness with vomiting, dehydration, or inability to maintain oral intake 7
- Perioperative period or prolonged fasting 2
- Signs of ketoacidosis (nausea, vomiting, abdominal pain, fatigue) 7
- Patients who lose ability to communicate thirst or maintain fluid intake 9
Do NOT discontinue simply because of high urinary glucose levels - this represents appropriate drug action and is associated with the medication's proven benefits in reducing cardiovascular death, heart failure hospitalization, and CKD progression 6, 7, 10.